TY - JOUR
TI - Salvage treatment with paclitaxel and gemcitabine for patients with
non-small-cell lung cancer after cisplatin- or docetaxel-based
chemotherapy: A multicenter phase II study
AU - Androulakis, N
AU - Kouroussis, C
AU - Kakolyris, S
AU - Tzannes, S and
AU - Papadakis, E
AU - Papadimitriou, C
AU - Geroyianni, A
AU - Georgopoulou, T
AU - and Dimopoulou, I
AU - Souglakos, J
AU - Kotsakis, A
AU - Vardakis, N and
AU - Hatzidaki, D
AU - Georgoulias, V
JO - Annals of Oncology
PY - 1998
VL - 9
TODO - 10
SP - 1127-1130
PB - KLUWER ACADEMIC PUBL
SN - 0923-7534, 1569-8041
TODO - 10.1023/A:1008497322508
TODO - gemcitabine; non-small-cell lung cancer; paclitaxel; phase II trial
TODO - Background. To evaluate the tolerance and efficacy of the combination of
paclitaxel and gemcitabine as salvage treatment in patients with
advanced non-small-cell lung cancer (NSCLC). Patients and methods.
Forty-nine patients with measurable NSCLC (PS 0-1: 80%; stage IV: 84%)
who progressed or failed first-line chemotherapy were enrolled. Prior
chemotherapy was cisplatin-based with (n = 20) or without (n = 22)
docetaxel and docetaxel-vinorelbine (n = 7).
Patients received gemcitabine (900 mg/m(2) i.v.; days 1 and 8) and
paclitaxel (175 mg/m(2); day 8) every three weeks; G-CSF (150 mu
g/m(2)/day s.c.; days 9-15) was given prophylactically to all patients.
Results: One (2%) complete and eight (16%) partial responses were
achieved (overall response 18%; 95% CI: 4%-24%); 14 patients (29%)
had stable disease and 26 (53%) progressive disease. Six responses were
observed in 17 patients who responded to first-line chemotherapy. The
median duration of response was seven months, the median TTP eight
months and the median survival 11 months. The one-year survival rate was
37%. Grade 3-4 neutropenia occured in six (12%) patients, grade 2-3
neurotoxicity in 16 (32%) and grade 2-3 asthenia in 25 (51%). Other
toxicities were mild.
Conclusions. The paclitaxel-gemcitabine combination is a well-tolerated
and relatively active salvage regimen in patients with NSCLC and it
merits further investigation.
ER -